AOD-9604 Dosage Guide: Protocols & Charts [2026]

AOD-9604 has human research behind it, but that research does not validate every injection protocol circulating online. This guide explains the actual trial routes, corrects concentration and weight-based arithmetic, and examines timing, cycling and combination claims.

Understanding AOD-9604 & Its Dosing Basis

AOD-9604 is a modified growth-hormone fragment, commonly described as Tyr-hGH(177–191): the terminal sequence with an added tyrosine. It should not be treated as interchangeable with every product called “HGH fragment 176–191.” The research rationale concerns lipid metabolism, not a demonstrated universal fat-loss regimen.

Preclinical evidence: Ng and colleagues found reduced body-weight gain and increased adipose lipolytic activity in obese rats given oral AOD9604. Reduced weight gain in rats is not the same endpoint as weight loss in people. Original rat study. A separate mouse study investigated beta-3-adrenergic pathways; its results did not identify AOD9604 as simply a direct beta-3 receptor agonist. Heffernan and colleagues.

Lipolysis means breakdown of stored fat; lipogenesis means lipid synthesis, whereas formation of new fat cells is adipogenesis. These processes are not interchangeable. A mechanistic finding also cannot establish comparative cost-effectiveness, a dose-response plateau or freedom from growth-hormone-related risks.

Starting Dosage: The Conservative Approach

The former 250 mcg starting dose and escalation to 300–500 mcg were presented as established subcutaneous treatment. The human evidence reviewed here does not validate that starting schedule. Beginning with a smaller quantity may reduce exposure, but does not by itself establish safety, effectiveness or the right formulation.

Unit conversion only: 250 mcg = 0.25 mg, and 500 mcg = 0.5 mg. Those equalities describe mass, not equivalence between oral and injectable delivery. Route, formulation and absorption still matter.

The former promise of increased energy, temperature or reduced appetite within 3–5 days was not substantiated. A subjective change does not demonstrate hypothalamic satiety signaling or confirm an effective dose. Keep a record of symptoms, product details and other changes for a clinical discussion instead of treating every early sensation as evidence that the peptide is working.

Standard Dosing Protocols & Schedules

Human evidence: Stier, Vos and Kenley summarized six randomized trials: early IV studies followed by oral studies. METAOD005 tested oral 1–30 mg daily for 12 weeks; METAOD006 randomized 502 adults to oral 0.25, 0.5 or 1 mg daily or placebo for 24 weeks. These are historical research doses, not recommended injection schedules. Published human safety summary.

The report describes favorable measured tolerability and no significant IGF-1 or glucose-tolerance differences in the longer studies; antibody testing in selected participants was negative. Trials were sponsor-funded and authors disclosed ownership or consulting relationships. Its broad no-related-serious-event wording is also inconsistent with a results passage describing diarrhea as possibly related to a high oral dose. Do not translate the summary into zero risk or an instruction to omit monitoring.

Efficacy matters separately: the sponsor reported in February 2007 that the larger oral obesity trial did not show statistically significant weight-loss benefit over placebo at 12 or 24 weeks and ended that obesity-development program. This is not proof that every future formulation must fail, but it contradicts presenting current injection protocols as proven by that program. Original sponsor trial-results announcement.

Beginner, intermediate, advanced and alternating “high-low” schedules appeared in the earlier article. None was supported by a matched human subcutaneous comparison. More frequent administration, larger quantities or a more complicated schedule should not be portrayed as a validated upgrade.

Injection Timing & Administration

Morning-fasted and pre-workout use are discussed in informal protocols. Personal reports may describe a routine or perceived response, but they do not establish that the timing caused a benefit. The reviewed human studies do not substantiate the former recommendation to inject 30–60 minutes before breakfast for maximum fat loss.

General changes in insulin or fuel use during fasting do not prove an AOD-9604 timing effect. The claims that food competes with injected AOD-9604 for uptake, that eating immediately blunts its effect, or that evening use is inferior were not supported by matched clinical evidence.

Nor does the previous “around seven minutes” half-life claim establish a human subcutaneous exposure profile or dosing interval. Drug concentration, duration of biological effects and measured clinical outcomes are different questions. Two 250 mcg amounts total 500 mcg arithmetically, but dividing a daily amount does not prove equal exposure, effectiveness or tolerability.

Subcutaneous Injection Technique

Subcutaneous means delivery into the tissue beneath the skin, but AOD-9604 has not been studied only by this route. The published human trial summary includes early intravenous studies and oral capsules or tablets. Those research routes are not instructions for self-administration and do not establish a standard subcutaneous regimen. Stier and colleagues, human trial safety summary.

Concentration correction: 10 mcg per 0.1 mL equals 100 mcg/mL; 10 mcg per 0.01 mL equals 1,000 mcg/mL. These are tenfold different concentrations, not interchangeable preparation examples. For a purely mathematical 10 mcg quantity, the corresponding volumes are 0.1 mL and 0.01 mL respectively. This example does not establish an AOD-9604 treatment dose, a suitable injectable formulation or a dilution recipe.

For any dispensed injectable, the exact product instructions and professional training must establish the route, concentration, device, preparation, storage and handling. Do not choose a diluent or syringe marking from this page. A universal needle gauge, angle, waiting time or site-spacing rule cannot establish correct delivery for every preparation; correct arithmetic alone does not verify sterility, stability, absorption or clinical suitability.

Cycling Strategies: On & Off Periods

Twelve weeks on/four weeks off and 16 weeks on/six weeks off were previously called standard cycles. The reviewed evidence does not establish those schedules, a hormonal reset, improved receptor sensitivity after a break, or retained fat loss attributable to AOD-9604. A 12-week study is not evidence for a four-week recovery interval.

Pulse dosing and “high-low” schedules are also unvalidated protocol claims in this context. A reduced-dose week still involves exposure; it is not equivalent to a drug-free interval. Subjective responses to breaks can inform research questions without proving prevention of tolerance.

Repeated cycles or continuous use need an evidence-based reassessment rather than an automatic calendar. Neither strategy is established here as a safe, effective long-term obesity treatment. Do not interpret a normal test or absence of noticeable symptoms as proof that a cycle is appropriate.

Dosage Charts by Body Weight

The prior chart divided users into under 140 lb, 140–180 lb, 180–220 lb and over 220 lb groups. The reviewed human evidence does not validate those bands as subcutaneous treatment instructions. Weight alone also cannot classify someone as fit, obese or safe to expose to a higher concentration.

Consistency check, not a regimen: the former rule of 2–3 mcg per pound would yield 400–600 mcg at 200 lb. That does not match the article's 400–500 mcg recommendation for the 180–220 lb band. Correcting the multiplication does not validate either the rule or the chart.

Under 140 lb: smaller body size does not by itself establish a 200–300 mcg dose. At 140–180 lb: an “average adult” label is not a dose-finding study. At 180–220 lb: greater body mass does not prove greater benefit from escalation. Above 220 lb: neither muscle mass nor obesity guarantees tolerance of higher exposure.

A useful assessment considers the indication, other treatment, organ function, actual product and measured outcomes. These considerations do not generate a validated AOD-9604 formula from body weight. The former automatic week-three increases should not be followed as evidence-based dosing.

Advanced Protocols & Stacking

Combining AOD-9604 with CJC-1295/GHRP-6, ipamorelin or tesamorelin remains a question about combination evidence—not just whether their proposed mechanisms sound complementary. The reviewed studies do not establish the former stack doses, superior fat loss, improved recovery or muscle preservation from those combinations.

The description of ipamorelin as a gentler option did not supply comparative safety data for an AOD-9604 stack. Likewise, evidence for another drug in a particular condition cannot be transferred to a combination or to general weight loss. This guide does not recommend adding a second peptide when the first has not produced a benefit.

Other AOD research should be kept in its own category. An intra-articular study reported cartilage and lameness findings in a rabbit osteoarthritis model, including a hyaluronic-acid combination. That is preclinical joint research, not a human subcutaneous fat-loss or stacking protocol. Original rabbit study.

People's experiences are worth recording with the product, route, concurrent treatments and objective outcomes identified. They should remain labeled as experiences rather than proof of causation. Discuss unexpected symptoms and available established options with the treating clinician instead of using an unverified stack to troubleshoot a lack of results.